nafamostat has been researched along with Injury, Myocardial Reperfusion in 9 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat mesilate was evaluated in 20 patients who underwent coronary artery bypass grafting." | 2.68 | Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. ( Fukuda, H; Kadoba, K; Masai, T; Matsuda, H; Ohata, T; Sawa, Y; Shimazaki, Y; Taniguchi, K, 1996) |
| " The dose-response characteristics of these three protease inhibitors were bell shaped, and the optimal concentrations of nafamostat mesilate, gabexate mesilate, and NCO-700 were 5 microM, 100 microM, and 20 microM, respectively." | 1.30 | Effects of protease inhibitors on postischemic recovery of the heart. ( Kinoshita, H; Shibata, T; Suehiro, S; Yamamoto, F, 1997) |
| " Post-ischemic recovery of AoF (%AoF) showed the bell-shaped dose-response curve, and the optimal dose was 3 microM (Exp." | 1.28 | [The effects of protease inhibitor upon the ischemia-reperfusion injury]. ( Kawashima, Y; Kinoshita, H; Nakajima, N; Ohashi, T; Shibata, T; Shimada, Y; Yamamoto, F, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwertz, H | 2 |
| Carter, JM | 1 |
| Russ, M | 1 |
| Schubert, S | 1 |
| Schlitt, A | 1 |
| Buerke, U | 1 |
| Schmidt, M | 2 |
| Hillen, H | 2 |
| Werdan, K | 1 |
| Buerke, M | 2 |
| La Bonte, LR | 2 |
| Dokken, B | 1 |
| Davis-Gorman, G | 2 |
| Stahl, GL | 2 |
| McDonagh, PF | 2 |
| Längin, T | 1 |
| Platsch, H | 1 |
| Richert, J | 1 |
| Bomm, S | 1 |
| Blaschke, G | 1 |
| Meyer, J | 1 |
| Darius, H | 1 |
| Sawa, Y | 2 |
| Shimazaki, Y | 1 |
| Kadoba, K | 1 |
| Masai, T | 1 |
| Fukuda, H | 1 |
| Ohata, T | 2 |
| Taniguchi, K | 1 |
| Matsuda, H | 2 |
| Shibata, T | 2 |
| Yamamoto, F | 2 |
| Suehiro, S | 1 |
| Kinoshita, H | 2 |
| Ichikawa, H | 1 |
| Kagisaki, K | 1 |
| Ohashi, T | 1 |
| Shimada, Y | 1 |
| Nakajima, N | 1 |
| Kawashima, Y | 1 |
| Homeister, JW | 1 |
| Satoh, P | 1 |
| Lucchesi, BR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest - a Randomized Clinical Trial[NCT03863015] | Phase 2 | 80 participants (Actual) | Interventional | 2019-03-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for nafamostat and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations.
Topics: Benzamidines; Cardiopulmonary Bypass; CD18 Antigens; Complement Hemolytic Activity Assay; Coronary A | 1996 |
Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium.
Topics: Animals; Benzamidines; Cell Hypoxia; Coronary Artery Bypass; Fibrinolysin; Guanidines; Humans; Inter | 1998 |
7 other studies available for nafamostat and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Complement Activation; Complement C1 | 2008 |
The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.
Topics: Animals; Antibodies, Monoclonal; Benzamidines; Complement C3; Complement Inactivating Agents; Diabet | 2009 |
Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits.
Topics: alpha-Crystallin B Chain; Animals; Benzamidines; Creatine Kinase; Electrophoresis, Gel, Two-Dimensio | 2002 |
Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion.
Topics: Animals; Benzamidines; Blood Cell Count; Blood Glucose; Blood Pressure; CD11b Antigen; Cell Adhesion | 2008 |
Effects of protease inhibitors on postischemic recovery of the heart.
Topics: Animals; Benzamidines; Creatine Kinase; Gabexate; Glycoproteins; Guanidines; Heart; In Vitro Techniq | 1997 |
[The effects of protease inhibitor upon the ischemia-reperfusion injury].
Topics: Animals; Benzamidines; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Guanidines; Magnesium | 1992 |
Effects of complement activation in the isolated heart. Role of the terminal complement components.
Topics: Animals; Benzamidines; Complement Activation; Complement C3a; Complement C5a; Complement Inactivator | 1992 |